Journals / European Journal of Rheumatology / 2022 / Cilt: 9 - Sayı: 1

Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study

Pages
26–30
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD).
📊
Key Findings & Data:Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict response to treatment with IL-6 receptor (IL-6R) antagonist tocilizumab.
💡
Conclusion & Impact:It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict response to treatment with IL-6 receptor (IL-6R) antagonist tocilizumab. Methods: Biological DMARD naïve patients of seropositive RA, fulfilling American College of Rheumatology/ European League Against Rheumatism classification criteria 2010, were treated with 06 doses of tocilizumab (8 mg/kg) at monthly interval. Baseline and post-treatment serum IL-6 levels were measured and correlated with response to treatment measured by disease activity score-28 joints erythrocyte sedimentation rate (DAS28 ESR) after treatment. Results: The study included 34 patients and 26 (70%) of them achieved DAS-28 remission (DAS28 ESR < 2.6). The baseline serum IL-6 did not correlate with post-treatment DAS28 ESR (R −0.197, P = .264). Though, statistically not significant (P = .085) more patients with comparatively lower baseline serum IL-6 attained DAS28 remission (16 out of 17, P = .085). There was an increase in the serum IL-6 level (median 40.5 pg/ml [IQR 130.2] to 72.6 pg/ml [IQR 162.5]) after tocilizumab treatment and the change in IL-6 level also did not correlate with post-treatment DAS28 ESR (R −0.240, P = .172). Conclusion: Higher number of patients with comparatively lower serum IL-6 level attained DAS28 remission in this study; however, it was not statistically significant. It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA.

🔖

Cite This Article

KUMAR, A., BHAKUNI, D. S., KARTIK, S., HEDGE, A., SHANMUGANANDAN, K., SINGH, K., VASDEV, V., MN, A. (2022). Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. European Journal of Rheumatology, Cilt: 9 - Sayı: 1, 26–30. https://ajindex.com/articles/511470

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Harris ED, Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med. 1990
  2. [Crossref] 2. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously–predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986
  3. Scott DL, Symmons DP, Coulton BL, et al. Longterm outcome of treating rheumatoid arthritis: Results after 20 years. Lancet. 1987
  4. [Crossref] 4. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008
  5. 371(9617):987-997. [Crossref] 5. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo- controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006
  6. [Crossref] 6. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005
  7. [Crossref] 7. Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: A review of potential biological markers of response. Ann Rheum Dis. 2011
  8. 70(12):2063-2070. [Crossref] 8. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988
  9. 18(11):1797-1801. [Crossref] 9. Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest. 1991
  10. 21(5):479-484. [Crossref] 10. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968
  11. 37 (147):393-406. 11. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: An American college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum. 2010
  12. [Crossref] 12. Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007
  13. [Crossref] 13. Scott LJ. Tocilizumab: A review in rheumatoid arthritis. Drugs